Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutically active pyrrolidine derivatives

a technology of pyrrolidine and derivatives, applied in the field of pyrrolidine derivatives, can solve the problems of significant problems in the management of preterm labor, undesired pregnancies, and perinatal morbidity and mortality

Inactive Publication Date: 2008-07-10
MERCK SERONO SA
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

"The patent text describes a new chemical compound that has specific chemical properties. The compound has various chemical groups attached to it, such as alkyl, aryl, heteroaryl, and others. These groups can have different carbon atoms and rings. The compound can also have different rings attached to it. The text also mentions the use of different atoms, such as fluoro, chloro, bromo, and iodo, and the use of sulfonyl groups. The technical effects of this new compound include improved performance and efficiency in various applications, such as in the field of electronics, sensors, and biomedical applications."

Problems solved by technology

Premature labor, though, and premature birth is undesired as it represents a major cause of perinatal morbidity and mortality.
Hence, the management of preterm labor represents a significant problem in the field of obstetrics.
Magnesium sulfate at plasma concentrations above the therapeutic range of 4 to 8 mg / dL can cause inhibition of cardiac conduction and neuromuscular transmission, respiratory depression and cardiac arrest, thus making this agent unsuitable when renal function is impaired.
Ethanol is as effective as ritodrine in preventing premature labor, but it does not produce a corresponding reduction in the incidence of fetal respiratory distress that administration of ritodrine does.
The principal drawback to the use of peptide antagonists including also atosiban is the problem of low oral bioavailability resulting from intestinal degradation.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutically active pyrrolidine derivatives
  • Pharmaceutically active pyrrolidine derivatives
  • Pharmaceutically active pyrrolidine derivatives

Examples

Experimental program
Comparison scheme
Effect test

example 1

General Procedure for the Saponification of the Olefin-Type Proline Methyl Esters, Such as Intermediates 3-6

[0372]A solution of sodium hydroxide (4.5 g, 112 mmol) in water (70 ml) was added to the relevant proline olefin methyl ester (66 mmol) in 3:1 dioxane:water (500 ml) and the reaction stirred for 3 h. The reaction mixture was then washed with diethyl ether (2×50 ml), and the aqueous phase acidified to pH 2 (0.1N HCl) and extracted into ethyl acetate. The ethyl acetate layer was then dried over magnesium sulfate, filtered and the solvent was then removed in vacuo to give the desired product in near quantitative yields as an oil which was used without further purification.

example 2

General Protocol for the Solution-Phase Synthesis of Oximether Pyrrolidine Derivatives of General Formula Ia (Scheme 1)

Method A: e.g. (2S,4EZ)-1-([1,1′-biphenyl]-4-ylcarbonyl)-N-(2-methoxyethyl)-4-(methoxyimino)-2-pyrrolidinecarboxamide

a) Protocol for the Formation of the Amide Bond

[0373]A solution was made containing the central building block, e.g. (2S,4EZ)-1-(tert-butoxycarbonyl)-4-(methoxyimino)-2-pyrrolidinecarboxylic acid (Intermediate 7) (1.5 g, 5.8 mmol), an amine or an amine salt, e.g. 2-methoxy-ethylamine (0.51 ml, 5.81 mmol) and DMAP (780 mg, 5.8 mmol) in DCM (30 ml). At 0° C., EDC (1.1 g, 5.8 mmol) was slowly added portion-wise. The reaction was slowly allowed to reach room temperature and was stirred overnight. The DCM was evaporated and the crude purified by column chromatography using EtOAc (100%) to collect the desired product, e.g. tert-butyl (2S,4EZ)-2-{[(2-meth-oxyethyl)amino]carbonyl}-4-(methoxyimino)-1-pyrrolidinecarboxylate (1.5 g, 80%) as a colourless oil.

[037...

example 3

(2S,4EZ)-1-([1,1′-biphenyl]-4-ylcarbonyl)-N-[2-(diethylamino)ethyl]-4-{[(4-methoxybenzyl)oxy]imino}-2-pyrrolidinecarboxamide

[0385]Following the general method as outlined in, Example 2, starting from (2S,4EZ)-1-(tert-butoxycarbonyl)-4-{[(4-methoxybenzyl)oxy]imino}-2-pyrrolidinecarboxylic acid, [1,1′-biphenyl]-4-carboxylic acid, and N1,N1-diethyl-1,2-ethanediamine the title compound was obtained after column chromatography as an off-white solid as a mixture of E / Z-isomers.

[0386]1H NMR (400 MHz, CDCl3); 1.05-1.15 (m, 6H), 2.7-2.8 (m, 1H), 2.9-3.2 (m, 6H), 3.4 (m, 1H), 3.6 (s, 3H), 4.0-4.1 (m, 1H), 4.3-4.4 (m, 1H), 3.75 (m, 1H), 3.8 (m, 2H), 6.65 (m, 2H), 7.0-7.1 (m, 2H), 7.2-7.3 (m, 3H), 7.35-7.45 (m, 6H), 8.8 (sibr, 0.5H). M+(APCI+); 543.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationsaaaaaaaaaa
enantiomeric excessaaaaaaaaaa
enantiomeric excessaaaaaaaaaa
Login to View More

Abstract

The present invention is related to pyrrolidine derivatives of formula I. Said compounds are preferably for use as pharmaceutically active compounds. Specifically, pyrrolidine derivatives of formula I are useful in the treatment and / or prevention of premature labor, premature birth and dysmenorrhea. In particular, the present invention is related to pyrrolidine derivatives displaying a substantial modulatory, notably an antagonist activity of the oxytocin receptor. More preferably, said compounds are useful in the treatment and / or prevention of disease states mediated by oxytocin, including premature labor, premature birth and dysmenorrhea. The present invention is furthermore related to novel pyrrolidine derivatives as well as to methods of their preparation.wherein X is selected from the group consisting of CR6R7, NOR6, NNR6R7;A is selected from the group consisting of —(C═O)—, —(C═O)—O—, —C(═NH)—, —(C═O)—NH—, —(C═S)—NH, —SO2—, —SO2NH—, —CH2—,B is either a group —C═O)—NR8R9 or represents a heterocyclic residue having the formula wherein Q is NR10, O or S; n is an integer selected of 0, 1 or 2;Y, Z and E form together with the 2 carbons to which they are attached a 5-6 membered aryl or heteroaryl ring.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This is a division of application Ser. No. 10 / 239,912, filed Feb. 10, 2003, which is a 371 national stage application of PCT / EP01 / 03171, filed Mar. 20, 2001. The entire contents of both applications being incorporated herein by reference.FIELD OF THE INVENTION[0002]The present invention is related to pyrrolidine derivatives. Said compounds are preferably for use as pharmaceutically active compounds. Specifically, pyrrolidine derivatives of formula I are useful in the treatment and / or prevention of premature labor, premature birth and dysmenorrhea. In particular, the present invention is related to pyrrolidine derivatives displaying a substantial modulatory, notably an antagonist activity of the oxytocin receptor. More preferably, said compounds are useful in the treatment and / or prevention of disease states mediated by oxytocin, including premature labor, premature birth and dysmenorrhea. The present invention is furthermore related to no...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/497A61K31/40A61K31/403A61P15/06C07D209/56C07D455/02C07D403/02C07D207/02A61P15/02A61K31/47C07D401/04A61K31/401A61K31/4015A61K31/402A61K31/4025A61K31/4184A61K31/433A61K31/4439A61K31/454A61K31/4545A61K31/4709A61K31/4725A61K31/496A61K31/506A61K31/517A61K31/5377A61P1/16A61P7/00A61P9/10A61P13/12A61P15/00A61P25/00A61P25/08A61P25/28A61P31/18A61P37/04A61P43/00C07B61/00C07D207/22C07D207/24C07D401/10C07D401/12C07D401/14C07D403/04C07D403/06C07D403/12C07D403/14C07D405/06C07D405/12C07D405/14C07D409/12C07D417/12
CPCC07D207/22C07D401/12C07D403/04C07D403/06C07D417/12C07D405/06C07D405/12C07D405/14C07D409/12C07D403/14A61P1/16A61P13/12A61P15/00A61P15/02A61P15/04A61P15/06A61P25/00A61P25/08A61P25/28A61P31/18A61P37/04A61P43/00A61P7/00A61P9/00A61P9/10Y02P20/55
Inventor HALAZY, SERGEQUATTROPANI, ANNASCHEER, ALEXANDERSCHWARZ, MATTHIASTHOMAS, RUSSELL J.BAXTER, ANTHONY
Owner MERCK SERONO SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com